Study of IGT001 for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a clinical diagnosis of retinitis pigmentosa.
- You have a known genetic mutation linked to retinal degeneration.
- You are willing to provide blood samples for genetic and HLA testing.
- Your blood counts, infections, and drug use are within normal limits.
- You are not pregnant or planning to become pregnant, and you agree to use birth control for a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests an implant called AuTNA I in adults with retinitis pigmentosa who currently have no or only very limited light perception. The goal is to see whether the implant can work safely and potentially improve vision in a carefully selected group of people.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.